Novel harmine derivatives for tumor targeted therapy
Metrics: PDF 1228 views | HTML 1032 views | ?
Siwen Li1,*, Aqin Wang1,*, Fan Gu1, Zhaohui Wang1, Caiping Tian1, Zhiyu Qian2, Liping Tang3, Yueqing Gu1
1Department of Biomedical Engineering, State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Arlington, TX, USA
2Department of Biomedical Engineering, School of Automation, Nanjing University of Aeronautics and Astronautics, Nanjing, China
3Department of Bioengineering, University of Texas at Arlington, Arlington, TX, USA
*These authors have contributed equally to this work
Yueqing Gu, e-mail: firstname.lastname@example.org
Keywords: harmine, structural modification, 2DG, met, tumor targeting therapy
Received: November 26, 2014 Accepted: April 10, 2015 Published: April 22, 2015
Harmine is a beta-carboline alkaloid found in medicinal plant PeganumHarmala, which has served as a folk anticancer medicine. However, clinical applications of harmine were limited by its low pharmacological effects and noticeable neurotoxicity. In this study, we modified harmine to increase the therapeutic efficacy and to decrease the systemic toxicity. Specifically, two tumor targeting harmine derivatives 2DG-Har-01 and MET-Har-02 were synthesized by modifying substituent in position-2, -7 and -9 of harmine ring with two different targeting group2-amino-2-deoxy-D-glucose (2DG) and Methionine (Met), respectively. Their therapeutic efficacy and toxicity were investigated both in vitro and in vivo. Results suggested that the two newharmine derivatives displayed much higher therapeutic effects than non-modified harmine. In particular, MET-Har-02 was more potent than 2DG-Har-01 with promising potential for targeted cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.